; (ii) any statement or characterization with respect to an applicable patent, including any statement or characterization of prior art, submitted by the sponsor of the application or holder of the approved application to the United States Patent and Trademark Office in support of patentability; and (iii) other information, as the Secretary or the Secretary of Commerce may require. (C) In this paragraph, the term applicable patent means— (i) a patent that— (I) claims a drug that is the subject of an application described in subparagraph (A), including any patent that claims, with respect to such a drug, a formulation or composition, method of use, or method of manufacturing; and (II) is issued, assigned, or licensed to the sponsor of the application or holder of the approved application described in subparagraph (A); (ii) an application for a patent described in clause (i)(I) that is sought by the sponsor of the application or holder of the approved application described in subparagraph (A); or (iii) such other patent or application for a patent as the Secretary determines appropriate. (D) (i) Except as provided in clause (ii), subparagraph (A) shall apply with respect to any original application submitted under this subsection on or after the date of enactment of the Medication Affordability and Patent Integrity Act and to any amendments or supplements to such original application. (ii) In the case of an application submitted before the date of enactment of the Medication Affordability and Patent Integrity Act , the requirements of subparagraph (A) apply with respect to— (I) any applicable patent issued on or after such date of enactment